A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations-Reference-Cited by-同舟云学术

A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations

Published:2023-10 Issue: Volume:184 Page:107349
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ninomiya Takashi^ORCID,Ishikawa Nobuhisa,Kozuki Toshiyuki,Kuyama Shoichi,Inoue Koji,Yokoyama Toshihide^ORCID,Kanaji Nobuhiro^ORCID,Yasugi Masayuki,Shibayama Takuo,Aoe Keisuke,Ochi Nobuaki,Fujitaka Kazunori,Kodani Masahiro,Ueda Yutaka,Watanabe Kazuhiko,Bessho Akihiro^ORCID,Sugimoto Keisuke,Oze Isao^ORCID,Hotta Katsuyuki^ORCID,Kiura Katsuyuki

Funder

Boehringer Ingelheim International GmbH

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference36 articles.

1. Global cancer statistics;Jemal;CA Cancer J. Clin.,2011

2. EGFR mutation incidence in non-Small-cell lung cancer of adenocarcinoma histology: A systematic review and global map by ethnicity (mutMapII);Midha;Am. J. Cancer Res.,2015

3. Overview of current systemic management of EGFR-mutant NSCLC;Hsu;Ann Oncol Off J Eur Soc Med Oncol,2018

4. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N. Engl. J. Med.,2010

5. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol.,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Afatinib Plus Bevacizumab Treatment for a Patient With EGFR S645C–Mutant Non–Small Cell Lung Cancer: A Case Report;JCO Precision Oncology;2024-06

2. The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer;Critical Reviews in Oncology/Hematology;2024-04

3. RETRACTION: Afatinib plus bevacizumab treatment for a patient with EGFR S645C-mutant NSCLC;Respiratory Medicine Case Reports;2024-04

4. Subtype of EGFR exon 19 deletion mutations;Translational Lung Cancer Research;2024-01

5. Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data;Translational Lung Cancer Research;2023-11